Efficacy and safety of Fondaparinux during thrombolytic therapy in acute ST-elevation myocardial infarction patients

摘要：

Background The aim of the study is to assess efficacy and safety of Fondaparinux during thrombolytic therapy in acute ST-elevation myocardial infarction patients.Methods From November 2011 to April 2012, patients with acute ST-elevation myocardial infarction and pain to hospital time within 6 hours were received thrombolytic therapy by recombinant tissue-type plasminogen activator(rt-PA).Before thrombolytic therapy, patients were randomly assigned to Fondaparinux group (2.5 mg, n=30) or standard heparin group (60 U/kg, maximum 4000 U, n=32).Coronary angiography or PCI were performed at 90 minutes after initiating study drugs.Primary endpoints of the trial were the rate of TIMI grade 3 flows at 90 minutes.Other endpoints included incidence of all-cause mortality at in-hospital, 30 days and 6 months, major bleeding and minor bleeding at in-hospital, 30 days and 6 months.

作者: ZHAO Xin HAN Ya-ling WANG Xiao-zeng XU Bai-ge

作者单位: Department of Cardiology,Institute of Cardiovascular Research of People”s Liberation Army,Shenyang Northern Hospital,Shenyang,Liaoning 110840,China

会议类型: 国内会议

会议名称: 第11届中国介入心脏病学大会

会议地点: 北京

会议语种:英文

页码: 274-274

在线出版日期: 2013-03-20（万方平台首次上网日期，不代表论文的发表时间）